Valneva (NASDAQ:VALN) Sees Unusually-High Trading Volume – Here’s Why

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) saw unusually-high trading volume on Monday . Approximately 52,339 shares were traded during mid-day trading, an increase of 12% from the previous session’s volume of 46,908 shares.The stock last traded at $6.2550 and had previously closed at $6.17.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen lowered shares of Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Valneva Stock Up 0.4%

The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.85 and a current ratio of 2.38. The stock’s 50 day moving average price is $9.92 and its 200-day moving average price is $9.61. The company has a market cap of $533.26 million, a PE ratio of -3.92 and a beta of 1.80.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.68) earnings per share for the quarter. Valneva had a negative return on equity of 76.81% and a negative net margin of 67.64%.The business had revenue of $55.92 million during the quarter. On average, analysts predict that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current year.

Hedge Funds Weigh In On Valneva

Several institutional investors and hedge funds have recently bought and sold shares of VALN. VSM Wealth Advisory LLC lifted its position in Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Valneva in the fourth quarter worth approximately $44,000. JPMorgan Chase & Co. bought a new position in shares of Valneva in the third quarter worth approximately $124,000. XTX Topco Ltd purchased a new position in shares of Valneva in the fourth quarter worth $94,000. Finally, Marex Group plc bought a new stake in Valneva during the 2nd quarter valued at $64,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.